ACTION and the Academic Research Consortium (ARC) aimed to harmonize definitions of pediatric and CHD AEs for use in clinical trials, registries, and regulatory evaluation.
Placement of a ventricular assist device (VAD) improves outcomes in children with advanced heart failure, but adverse events remain important consequences. Preoperative mechanical ventilation (MV) increases mortality, but it is unknown what impact prolonged postoperative MV has.
Abstract Advanced Cardiac Therapies Improving Outcomes Network (ACTION) and Pediatric Heart Transplant Society (PHTS) convened a working group at the beginning of 2020 during the COVID-19 pandemic, with the aim
ACTION set forth to report current outcomes in patients supported with the HeartMate 3 ventricular assist device in a multicenter learning network.
Expanding Use of the HeartMate 3 VAD in Pediatric and Adult Patients within the ACTION Read More »
Purpose Cardiac disease results in significant morbidity and mortality in patients with muscular dystrophy (MD). Single centers have reported their ventricular assist device (VAD) experience in specific MDs and in
Despite the fact that VADs are now regarded as an important treatment option in pediatric heart failure, most hospitals perform less than 10 VAD surgeries in children a year. “ISHLT
ISHLT Consensus Statement for the Selection and Management of Pediatric and CHD on VAD Read More »
COVID 19 infection in children causes a hyper-inflammatory syndrome referred to as multisystem inflammatory syndrome in children (MIS-C). This ACTION publication, published June 2, 2021 in Pediatric Cardiology, provides a
MIS-C Associated with COVID-19 Anti-thrombosis Guideline of Care for Children Read More »
Cerebrovascular accidents (CVA) are a common problem in pediatric VAD support. This Pedimacs analysis investigates rates, risk factors, and outcomes The field of pediatric mechanical circulatory support changed dramatically when
Berlin Heart EXCOR and ACTION Post-Approval Surveillance Study Report Read More »
A MULTICENTER REGISTRY ANALYSIS The HeartMate 3™ LVAD was originally designed for use in adults with heart failure. This study, published in the Journal of Heart and Lung Transplantation on
